HRT and GLP-1 receptor agonists address different levels of the same biological disruption. HRT acts upstream, restoring the hormonal signaling environment that menopause withdraws. GLP-1 receptor agonists act downstream, targeting the visceral fat accumulation, insulin resistance, and dysregulated appetite that estrogen’s absence creates. They are complementary tools, not alternatives.